High-density lipoprotein subfractions and risk of coronary artery disease
- 90 Downloads
Numerous studies have shown that levels of high-density lipoprotein (HDL) cholesterol are inversely related to coronary artery disease risk. The HDL subfractions, however, seem to differ in their capacity to confer protection, with the large HDL2 subfraction appearing to be more important than the small HDL3 subfraction. Lipid-modifying drugs differ in their HDL-raising efficacy, and they also differ in how they affect HDL subfractions. Clinical trials show that raising total HDL cholesterol improves clinical and angiographic outcomes. It remains to be determined, however, whether a shift in distribution of HDL particles provides greater benefit than just an increase in total HDL.
KeywordsCholesteryl Ester Transfer Protein Coronary Artery Disease Risk Arterioscler Thromb Vasc Biol Reverse Cholesterol Transport Cholesterol Ester Transfer Protein
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 28.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106: 3143–3421.Google Scholar
- 39.Rubins HB, Robins SJ, Collins D, et al., for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341: 410–418.PubMedCrossRefGoogle Scholar
- 40.Syvänne M, Nieminen MS, Frick MH, et al., for the Lopid Coronary Angiography Trial (LOCAT) Study Group: Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation 1998, 98: 1993–1999.PubMedGoogle Scholar
- 41.Ruotolo G, Ericsson CG, Tettamanti C, et al.: Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998, 32: 1648–1656.PubMedCrossRefGoogle Scholar
- 42.Krause BR, Auerbach BJ: Reverse cholesterol transport and future pharmacological approaches to the treatment of atherosclerosis. Curr Opin Invest Drug 2001, 2: 375–381.Google Scholar